GlaxoSmithKline said Monday that a Phase 2 trial of its COVID-19 vaccine, developed with French partner Sanofi, showed a "strong neutralizing antibody response" in adult participates of all age groups and raised no safety issues. "We believe that this vaccine candidate can make a significant contribution to the ongoing fight against COVID-19 and will move to Phase 3 as soon as possible to meet our goal of making it available before the end of the year," said Roger Connor, president of GSK's vaccines program.
The Phase 3 trial, expected to start in the next few weeks, is slated to involve 35,000 adults from a number of countries. The vaccine is based on Sanofi's seasonal flu vaccine, combined with an immunity-boosting adjuvant from GSK. The companies had hoped to seek regulatory approval in the first half of 2021, but pushed back those plans after disappointing results in December. The favorable new findings will help GSK CEO Emma Walmsley stave off pressure from activist investor Elliott Management, which took a large stake in GSK in April, The Guardian reports.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Create an account with the same email registered to your subscription to unlock access.
-
5 sleeper hit cartoons about Trump's struggles to stay awake in courtCartoons Artists take on courtroom tranquility, war on wokeness, and more
-
The true story of Feud: Capote vs. The SwansIn depth The writer's fall from grace with his high-flying socialite friends in 1960s Manhattan is captured in a new Disney+ series
-
Scottie Scheffler: victory for the 'pre-eminent golfer of this era'Why Everyone's Talking About Masters victory is Scheffler's second in three years
-
Texas dairy worker gets bird flu from infected cowSpeed Read The virus has been spreading among cattle in Texas, Kansas, Michigan and New Mexico
-
Dengue hits the Americas hard and earlySpeed Read Puerto Rico has declared an epidemic as dengue cases surge
-
Covid four years on: have we got over the pandemic?Today's Big Question Brits suffering from both lockdown nostalgia and collective trauma that refuses to go away
-
US bans final type of asbestosSpeed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
-
The hollow classroomOpinion Remote school let kids down. It will take much more than extra tutoring for kids to recover.
-
Excess screen time is making children only see what is in front of themUnder the radar The future is looking blurry. And very nearsighted.
-
Covid-19: what to know about UK's new Juno and Pirola variantsin depth Rapidly spreading new JN.1 strain is 'yet another reminder that the pandemic is far from over'
-
Long-term respiratory illness is here to stayThe Explainer Covid is not the only disease with a long version
